Global Alpha-1 Lung Disease Market Insights, Forecast to 2029
This report presents an overview of global market for Alpha-1 Lung Disease market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Alpha-1 Lung Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Alpha-1 Lung Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Alpha-1 Lung Disease revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Alpha-1 Lung Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Alpha-1 Lung Disease revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Alpha-1 Lung Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha-1 Lung Disease companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha-1 Lung Disease revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Alpha-1 Lung Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Alpha-1 Lung Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Alpha-1 Lung Disease revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Alpha-1 Lung Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Alpha-1 Lung Disease revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
By Company
- Pfizer
- Baxter
- AstraZeneca
- Grifols
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Kamada Ltd
- GlaxoSmithKline
- CSL Behring
- Takeda
- LFB Biomedicaments
- Abeona Therapeutics
- Biogen
- Vertex Pharmaceuticals
- Baxalta
- Arrowhead Research Corporation
- ProBioGen
- Chiesi Pharmaceuticals
- Kedrion Group
- ProMetic Life Sciences
- Augmentation Therapy
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
- Hospitals
- Specialty Clinics
- Pharmacies
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Alpha-1 Lung Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha-1 Lung Disease companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha-1 Lung Disease revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Alpha-1 Lung Disease Market Perspective (2018-2029)
2.2 Global Alpha-1 Lung Disease Growth Trends by Region
2.2.1 Alpha-1 Lung Disease Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Alpha-1 Lung Disease Historic Market Size by Region (2018-2023)
2.2.3 Alpha-1 Lung Disease Forecasted Market Size by Region (2024-2029)
2.3 Alpha-1 Lung Disease Market Dynamics
2.3.1 Alpha-1 Lung Disease Industry Trends
2.3.2 Alpha-1 Lung Disease Market Drivers
2.3.3 Alpha-1 Lung Disease Market Challenges
2.3.4 Alpha-1 Lung Disease Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Alpha-1 Lung Disease by Players
3.1.1 Global Alpha-1 Lung Disease Revenue by Players (2018-2023)
3.1.2 Global Alpha-1 Lung Disease Revenue Market Share by Players (2018-2023)
3.2 Global Alpha-1 Lung Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Alpha-1 Lung Disease, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Alpha-1 Lung Disease Market Concentration Ratio
3.4.1 Global Alpha-1 Lung Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha-1 Lung Disease Revenue in 2022
3.5 Global Key Players of Alpha-1 Lung Disease Head office and Area Served
3.6 Global Key Players of Alpha-1 Lung Disease, Product and Application
3.7 Global Key Players of Alpha-1 Lung Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ALPHA-1 LUNG DISEASE BREAKDOWN DATA BY TYPE
4.1 Global Alpha-1 Lung Disease Historic Market Size by Type (2018-2023)
4.2 Global Alpha-1 Lung Disease Forecasted Market Size by Type (2024-2029)
5 ALPHA-1 LUNG DISEASE BREAKDOWN DATA BY APPLICATION
5.1 Global Alpha-1 Lung Disease Historic Market Size by Application (2018-2023)
5.2 Global Alpha-1 Lung Disease Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Alpha-1 Lung Disease Market Size (2018-2029)
6.2 North America Alpha-1 Lung Disease Market Size by Type
6.2.1 North America Alpha-1 Lung Disease Market Size by Type (2018-2023)
6.2.2 North America Alpha-1 Lung Disease Market Size by Type (2024-2029)
6.2.3 North America Alpha-1 Lung Disease Market Share by Type (2018-2029)
6.3 North America Alpha-1 Lung Disease Market Size by Application
6.3.1 North America Alpha-1 Lung Disease Market Size by Application (2018-2023)
6.3.2 North America Alpha-1 Lung Disease Market Size by Application (2024-2029)
6.3.3 North America Alpha-1 Lung Disease Market Share by Application (2018-2029)
6.4 North America Alpha-1 Lung Disease Market Size by Country
6.4.1 North America Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Alpha-1 Lung Disease Market Size by Country (2018-2023)
6.4.3 North America Alpha-1 Lung Disease Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Alpha-1 Lung Disease Market Size (2018-2029)
7.2 Europe Alpha-1 Lung Disease Market Size by Type
7.2.1 Europe Alpha-1 Lung Disease Market Size by Type (2018-2023)
7.2.2 Europe Alpha-1 Lung Disease Market Size by Type (2024-2029)
7.2.3 Europe Alpha-1 Lung Disease Market Share by Type (2018-2029)
7.3 Europe Alpha-1 Lung Disease Market Size by Application
7.3.1 Europe Alpha-1 Lung Disease Market Size by Application (2018-2023)
7.3.2 Europe Alpha-1 Lung Disease Market Size by Application (2024-2029)
7.3.3 Europe Alpha-1 Lung Disease Market Share by Application (2018-2029)
7.4 Europe Alpha-1 Lung Disease Market Size by Country
7.4.1 Europe Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Alpha-1 Lung Disease Market Size by Country (2018-2023)
7.4.3 Europe Alpha-1 Lung Disease Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Alpha-1 Lung Disease Market Size (2018-2029)
8.2 China Alpha-1 Lung Disease Market Size by Type
8.2.1 China Alpha-1 Lung Disease Market Size by Type (2018-2023)
8.2.2 China Alpha-1 Lung Disease Market Size by Type (2024-2029)
8.2.3 China Alpha-1 Lung Disease Market Share by Type (2018-2029)
8.3 China Alpha-1 Lung Disease Market Size by Application
8.3.1 China Alpha-1 Lung Disease Market Size by Application (2018-2023)
8.3.2 China Alpha-1 Lung Disease Market Size by Application (2024-2029)
8.3.3 China Alpha-1 Lung Disease Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Alpha-1 Lung Disease Market Size (2018-2029)
9.2 Asia Alpha-1 Lung Disease Market Size by Type
9.2.1 Asia Alpha-1 Lung Disease Market Size by Type (2018-2023)
9.2.2 Asia Alpha-1 Lung Disease Market Size by Type (2024-2029)
9.2.3 Asia Alpha-1 Lung Disease Market Share by Type (2018-2029)
9.3 Asia Alpha-1 Lung Disease Market Size by Application
9.3.1 Asia Alpha-1 Lung Disease Market Size by Application (2018-2023)
9.3.2 Asia Alpha-1 Lung Disease Market Size by Application (2024-2029)
9.3.3 Asia Alpha-1 Lung Disease Market Share by Application (2018-2029)
9.4 Asia Alpha-1 Lung Disease Market Size by Region
9.4.1 Asia Alpha-1 Lung Disease Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Alpha-1 Lung Disease Market Size by Region (2018-2023)
9.4.3 Asia Alpha-1 Lung Disease Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type
10.2.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application
10.3.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country
10.4.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha-1 Lung Disease Introduction
11.1.4 Pfizer Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.1.5 Pfizer Recent Developments
11.2 Baxter
11.2.1 Baxter Company Details
11.2.2 Baxter Business Overview
11.2.3 Baxter Alpha-1 Lung Disease Introduction
11.2.4 Baxter Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.2.5 Baxter Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha-1 Lung Disease Introduction
11.3.4 AstraZeneca Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.3.5 AstraZeneca Recent Developments
11.4 Grifols
11.4.1 Grifols Company Details
11.4.2 Grifols Business Overview
11.4.3 Grifols Alpha-1 Lung Disease Introduction
11.4.4 Grifols Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.4.5 Grifols Recent Developments
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Details
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Alpha-1 Lung Disease Introduction
11.6.4 Boehringer Ingelheim Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.6.5 Boehringer Ingelheim Recent Developments
11.7 Kamada Ltd
11.7.1 Kamada Ltd Company Details
11.7.2 Kamada Ltd Business Overview
11.7.3 Kamada Ltd Alpha-1 Lung Disease Introduction
11.7.4 Kamada Ltd Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.7.5 Kamada Ltd Recent Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Alpha-1 Lung Disease Introduction
11.8.4 GlaxoSmithKline Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.8.5 GlaxoSmithKline Recent Developments
11.9 CSL Behring
11.9.1 CSL Behring Company Details
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha-1 Lung Disease Introduction
11.9.4 CSL Behring Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.9.5 CSL Behring Recent Developments
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Alpha-1 Lung Disease Introduction
11.10.4 Takeda Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.10.5 Takeda Recent Developments
11.11 LFB Biomedicaments
11.11.1 LFB Biomedicaments Company Details
11.11.2 LFB Biomedicaments Business Overview
11.11.3 LFB Biomedicaments Alpha-1 Lung Disease Introduction
11.11.4 LFB Biomedicaments Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.11.5 LFB Biomedicaments Recent Developments
11.12 Abeona Therapeutics
11.12.1 Abeona Therapeutics Company Details
11.12.2 Abeona Therapeutics Business Overview
11.12.3 Abeona Therapeutics Alpha-1 Lung Disease Introduction
11.12.4 Abeona Therapeutics Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.12.5 Abeona Therapeutics Recent Developments
11.13 Biogen
11.13.1 Biogen Company Details
11.13.2 Biogen Business Overview
11.13.3 Biogen Alpha-1 Lung Disease Introduction
11.13.4 Biogen Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.13.5 Biogen Recent Developments
11.14 Vertex Pharmaceuticals
11.14.1 Vertex Pharmaceuticals Company Details
11.14.2 Vertex Pharmaceuticals Business Overview
11.14.3 Vertex Pharmaceuticals Alpha-1 Lung Disease Introduction
11.14.4 Vertex Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.14.5 Vertex Pharmaceuticals Recent Developments
11.15 Baxalta
11.15.1 Baxalta Company Details
11.15.2 Baxalta Business Overview
11.15.3 Baxalta Alpha-1 Lung Disease Introduction
11.15.4 Baxalta Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.15.5 Baxalta Recent Developments
11.16 Arrowhead Research Corporation
11.16.1 Arrowhead Research Corporation Company Details
11.16.2 Arrowhead Research Corporation Business Overview
11.16.3 Arrowhead Research Corporation Alpha-1 Lung Disease Introduction
11.16.4 Arrowhead Research Corporation Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.16.5 Arrowhead Research Corporation Recent Developments
11.17 ProBioGen
11.17.1 ProBioGen Company Details
11.17.2 ProBioGen Business Overview
11.17.3 ProBioGen Alpha-1 Lung Disease Introduction
11.17.4 ProBioGen Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.17.5 ProBioGen Recent Developments
11.18 Chiesi Pharmaceuticals
11.18.1 Chiesi Pharmaceuticals Company Details
11.18.2 Chiesi Pharmaceuticals Business Overview
11.18.3 Chiesi Pharmaceuticals Alpha-1 Lung Disease Introduction
11.18.4 Chiesi Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.18.5 Chiesi Pharmaceuticals Recent Developments
11.19 Kedrion Group
11.19.1 Kedrion Group Company Details
11.19.2 Kedrion Group Business Overview
11.19.3 Kedrion Group Alpha-1 Lung Disease Introduction
11.19.4 Kedrion Group Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.19.5 Kedrion Group Recent Developments
11.20 ProMetic Life Sciences
11.20.1 ProMetic Life Sciences Company Details
11.20.2 ProMetic Life Sciences Business Overview
11.20.3 ProMetic Life Sciences Alpha-1 Lung Disease Introduction
11.20.4 ProMetic Life Sciences Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.20.5 ProMetic Life Sciences Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Alpha-1 Lung Disease Market Perspective (2018-2029)
2.2 Global Alpha-1 Lung Disease Growth Trends by Region
2.2.1 Alpha-1 Lung Disease Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Alpha-1 Lung Disease Historic Market Size by Region (2018-2023)
2.2.3 Alpha-1 Lung Disease Forecasted Market Size by Region (2024-2029)
2.3 Alpha-1 Lung Disease Market Dynamics
2.3.1 Alpha-1 Lung Disease Industry Trends
2.3.2 Alpha-1 Lung Disease Market Drivers
2.3.3 Alpha-1 Lung Disease Market Challenges
2.3.4 Alpha-1 Lung Disease Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Alpha-1 Lung Disease by Players
3.1.1 Global Alpha-1 Lung Disease Revenue by Players (2018-2023)
3.1.2 Global Alpha-1 Lung Disease Revenue Market Share by Players (2018-2023)
3.2 Global Alpha-1 Lung Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Alpha-1 Lung Disease, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Alpha-1 Lung Disease Market Concentration Ratio
3.4.1 Global Alpha-1 Lung Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha-1 Lung Disease Revenue in 2022
3.5 Global Key Players of Alpha-1 Lung Disease Head office and Area Served
3.6 Global Key Players of Alpha-1 Lung Disease, Product and Application
3.7 Global Key Players of Alpha-1 Lung Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ALPHA-1 LUNG DISEASE BREAKDOWN DATA BY TYPE
4.1 Global Alpha-1 Lung Disease Historic Market Size by Type (2018-2023)
4.2 Global Alpha-1 Lung Disease Forecasted Market Size by Type (2024-2029)
5 ALPHA-1 LUNG DISEASE BREAKDOWN DATA BY APPLICATION
5.1 Global Alpha-1 Lung Disease Historic Market Size by Application (2018-2023)
5.2 Global Alpha-1 Lung Disease Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Alpha-1 Lung Disease Market Size (2018-2029)
6.2 North America Alpha-1 Lung Disease Market Size by Type
6.2.1 North America Alpha-1 Lung Disease Market Size by Type (2018-2023)
6.2.2 North America Alpha-1 Lung Disease Market Size by Type (2024-2029)
6.2.3 North America Alpha-1 Lung Disease Market Share by Type (2018-2029)
6.3 North America Alpha-1 Lung Disease Market Size by Application
6.3.1 North America Alpha-1 Lung Disease Market Size by Application (2018-2023)
6.3.2 North America Alpha-1 Lung Disease Market Size by Application (2024-2029)
6.3.3 North America Alpha-1 Lung Disease Market Share by Application (2018-2029)
6.4 North America Alpha-1 Lung Disease Market Size by Country
6.4.1 North America Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Alpha-1 Lung Disease Market Size by Country (2018-2023)
6.4.3 North America Alpha-1 Lung Disease Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Alpha-1 Lung Disease Market Size (2018-2029)
7.2 Europe Alpha-1 Lung Disease Market Size by Type
7.2.1 Europe Alpha-1 Lung Disease Market Size by Type (2018-2023)
7.2.2 Europe Alpha-1 Lung Disease Market Size by Type (2024-2029)
7.2.3 Europe Alpha-1 Lung Disease Market Share by Type (2018-2029)
7.3 Europe Alpha-1 Lung Disease Market Size by Application
7.3.1 Europe Alpha-1 Lung Disease Market Size by Application (2018-2023)
7.3.2 Europe Alpha-1 Lung Disease Market Size by Application (2024-2029)
7.3.3 Europe Alpha-1 Lung Disease Market Share by Application (2018-2029)
7.4 Europe Alpha-1 Lung Disease Market Size by Country
7.4.1 Europe Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Alpha-1 Lung Disease Market Size by Country (2018-2023)
7.4.3 Europe Alpha-1 Lung Disease Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Alpha-1 Lung Disease Market Size (2018-2029)
8.2 China Alpha-1 Lung Disease Market Size by Type
8.2.1 China Alpha-1 Lung Disease Market Size by Type (2018-2023)
8.2.2 China Alpha-1 Lung Disease Market Size by Type (2024-2029)
8.2.3 China Alpha-1 Lung Disease Market Share by Type (2018-2029)
8.3 China Alpha-1 Lung Disease Market Size by Application
8.3.1 China Alpha-1 Lung Disease Market Size by Application (2018-2023)
8.3.2 China Alpha-1 Lung Disease Market Size by Application (2024-2029)
8.3.3 China Alpha-1 Lung Disease Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Alpha-1 Lung Disease Market Size (2018-2029)
9.2 Asia Alpha-1 Lung Disease Market Size by Type
9.2.1 Asia Alpha-1 Lung Disease Market Size by Type (2018-2023)
9.2.2 Asia Alpha-1 Lung Disease Market Size by Type (2024-2029)
9.2.3 Asia Alpha-1 Lung Disease Market Share by Type (2018-2029)
9.3 Asia Alpha-1 Lung Disease Market Size by Application
9.3.1 Asia Alpha-1 Lung Disease Market Size by Application (2018-2023)
9.3.2 Asia Alpha-1 Lung Disease Market Size by Application (2024-2029)
9.3.3 Asia Alpha-1 Lung Disease Market Share by Application (2018-2029)
9.4 Asia Alpha-1 Lung Disease Market Size by Region
9.4.1 Asia Alpha-1 Lung Disease Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Alpha-1 Lung Disease Market Size by Region (2018-2023)
9.4.3 Asia Alpha-1 Lung Disease Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type
10.2.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application
10.3.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country
10.4.1 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha-1 Lung Disease Introduction
11.1.4 Pfizer Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.1.5 Pfizer Recent Developments
11.2 Baxter
11.2.1 Baxter Company Details
11.2.2 Baxter Business Overview
11.2.3 Baxter Alpha-1 Lung Disease Introduction
11.2.4 Baxter Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.2.5 Baxter Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha-1 Lung Disease Introduction
11.3.4 AstraZeneca Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.3.5 AstraZeneca Recent Developments
11.4 Grifols
11.4.1 Grifols Company Details
11.4.2 Grifols Business Overview
11.4.3 Grifols Alpha-1 Lung Disease Introduction
11.4.4 Grifols Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.4.5 Grifols Recent Developments
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Details
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Alpha-1 Lung Disease Introduction
11.6.4 Boehringer Ingelheim Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.6.5 Boehringer Ingelheim Recent Developments
11.7 Kamada Ltd
11.7.1 Kamada Ltd Company Details
11.7.2 Kamada Ltd Business Overview
11.7.3 Kamada Ltd Alpha-1 Lung Disease Introduction
11.7.4 Kamada Ltd Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.7.5 Kamada Ltd Recent Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Alpha-1 Lung Disease Introduction
11.8.4 GlaxoSmithKline Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.8.5 GlaxoSmithKline Recent Developments
11.9 CSL Behring
11.9.1 CSL Behring Company Details
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha-1 Lung Disease Introduction
11.9.4 CSL Behring Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.9.5 CSL Behring Recent Developments
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Alpha-1 Lung Disease Introduction
11.10.4 Takeda Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.10.5 Takeda Recent Developments
11.11 LFB Biomedicaments
11.11.1 LFB Biomedicaments Company Details
11.11.2 LFB Biomedicaments Business Overview
11.11.3 LFB Biomedicaments Alpha-1 Lung Disease Introduction
11.11.4 LFB Biomedicaments Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.11.5 LFB Biomedicaments Recent Developments
11.12 Abeona Therapeutics
11.12.1 Abeona Therapeutics Company Details
11.12.2 Abeona Therapeutics Business Overview
11.12.3 Abeona Therapeutics Alpha-1 Lung Disease Introduction
11.12.4 Abeona Therapeutics Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.12.5 Abeona Therapeutics Recent Developments
11.13 Biogen
11.13.1 Biogen Company Details
11.13.2 Biogen Business Overview
11.13.3 Biogen Alpha-1 Lung Disease Introduction
11.13.4 Biogen Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.13.5 Biogen Recent Developments
11.14 Vertex Pharmaceuticals
11.14.1 Vertex Pharmaceuticals Company Details
11.14.2 Vertex Pharmaceuticals Business Overview
11.14.3 Vertex Pharmaceuticals Alpha-1 Lung Disease Introduction
11.14.4 Vertex Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.14.5 Vertex Pharmaceuticals Recent Developments
11.15 Baxalta
11.15.1 Baxalta Company Details
11.15.2 Baxalta Business Overview
11.15.3 Baxalta Alpha-1 Lung Disease Introduction
11.15.4 Baxalta Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.15.5 Baxalta Recent Developments
11.16 Arrowhead Research Corporation
11.16.1 Arrowhead Research Corporation Company Details
11.16.2 Arrowhead Research Corporation Business Overview
11.16.3 Arrowhead Research Corporation Alpha-1 Lung Disease Introduction
11.16.4 Arrowhead Research Corporation Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.16.5 Arrowhead Research Corporation Recent Developments
11.17 ProBioGen
11.17.1 ProBioGen Company Details
11.17.2 ProBioGen Business Overview
11.17.3 ProBioGen Alpha-1 Lung Disease Introduction
11.17.4 ProBioGen Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.17.5 ProBioGen Recent Developments
11.18 Chiesi Pharmaceuticals
11.18.1 Chiesi Pharmaceuticals Company Details
11.18.2 Chiesi Pharmaceuticals Business Overview
11.18.3 Chiesi Pharmaceuticals Alpha-1 Lung Disease Introduction
11.18.4 Chiesi Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.18.5 Chiesi Pharmaceuticals Recent Developments
11.19 Kedrion Group
11.19.1 Kedrion Group Company Details
11.19.2 Kedrion Group Business Overview
11.19.3 Kedrion Group Alpha-1 Lung Disease Introduction
11.19.4 Kedrion Group Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.19.5 Kedrion Group Recent Developments
11.20 ProMetic Life Sciences
11.20.1 ProMetic Life Sciences Company Details
11.20.2 ProMetic Life Sciences Business Overview
11.20.3 ProMetic Life Sciences Alpha-1 Lung Disease Introduction
11.20.4 ProMetic Life Sciences Revenue in Alpha-1 Lung Disease Business (2018-2023)
11.20.5 ProMetic Life Sciences Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Alpha-1 Lung Disease Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Other
Table 6. Global Alpha-1 Lung Disease Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Alpha-1 Lung Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Alpha-1 Lung Disease Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Alpha-1 Lung Disease Market Share by Region (2018-2023)
Table 10. Global Alpha-1 Lung Disease Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Alpha-1 Lung Disease Market Share by Region (2024-2029)
Table 12. Alpha-1 Lung Disease Market Trends
Table 13. Alpha-1 Lung Disease Market Drivers
Table 14. Alpha-1 Lung Disease Market Challenges
Table 15. Alpha-1 Lung Disease Market Restraints
Table 16. Global Alpha-1 Lung Disease Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Alpha-1 Lung Disease Revenue Share by Players (2018-2023)
Table 18. Global Top Alpha-1 Lung Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Lung Disease as of 2022)
Table 19. Global Alpha-1 Lung Disease Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Alpha-1 Lung Disease Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Alpha-1 Lung Disease, Headquarters and Area Served
Table 22. Global Key Players of Alpha-1 Lung Disease, Product and Application
Table 23. Global Key Players of Alpha-1 Lung Disease, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Alpha-1 Lung Disease Revenue Market Share by Type (2018-2023)
Table 27. Global Alpha-1 Lung Disease Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Alpha-1 Lung Disease Revenue Market Share by Type (2024-2029)
Table 29. Global Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Alpha-1 Lung Disease Revenue Share by Application (2018-2023)
Table 31. Global Alpha-1 Lung Disease Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Alpha-1 Lung Disease Revenue Share by Application (2024-2029)
Table 33. North America Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Alpha-1 Lung Disease Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Alpha-1 Lung Disease Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Alpha-1 Lung Disease Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Alpha-1 Lung Disease Product
Table 68. Pfizer Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 69. Pfizer Recent Developments
Table 70. Baxter Company Details
Table 71. Baxter Business Overview
Table 72. Baxter Alpha-1 Lung Disease Product
Table 73. Baxter Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 74. Baxter Recent Developments
Table 75. AstraZeneca Company Details
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Alpha-1 Lung Disease Product
Table 78. AstraZeneca Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 79. AstraZeneca Recent Developments
Table 80. Grifols Company Details
Table 81. Grifols Business Overview
Table 82. Grifols Alpha-1 Lung Disease Product
Table 83. Grifols Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 84. Grifols Recent Developments
Table 85. Teva Pharmaceutical Industries Company Details
Table 86. Teva Pharmaceutical Industries Business Overview
Table 87. Teva Pharmaceutical Industries Alpha-1 Lung Disease Product
Table 88. Teva Pharmaceutical Industries Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 89. Teva Pharmaceutical Industries Recent Developments
Table 90. Boehringer Ingelheim Company Details
Table 91. Boehringer Ingelheim Business Overview
Table 92. Boehringer Ingelheim Alpha-1 Lung Disease Product
Table 93. Boehringer Ingelheim Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 94. Boehringer Ingelheim Recent Developments
Table 95. Kamada Ltd Company Details
Table 96. Kamada Ltd Business Overview
Table 97. Kamada Ltd Alpha-1 Lung Disease Product
Table 98. Kamada Ltd Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 99. Kamada Ltd Recent Developments
Table 100. GlaxoSmithKline Company Details
Table 101. GlaxoSmithKline Business Overview
Table 102. GlaxoSmithKline Alpha-1 Lung Disease Product
Table 103. GlaxoSmithKline Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 104. GlaxoSmithKline Recent Developments
Table 105. CSL Behring Company Details
Table 106. CSL Behring Business Overview
Table 107. CSL Behring Alpha-1 Lung Disease Product
Table 108. CSL Behring Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 109. CSL Behring Recent Developments
Table 110. Takeda Company Details
Table 111. Takeda Business Overview
Table 112. Takeda Alpha-1 Lung Disease Product
Table 113. Takeda Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 114. Takeda Recent Developments
Table 115. LFB Biomedicaments Company Details
Table 116. LFB Biomedicaments Business Overview
Table 117. LFB Biomedicaments Alpha-1 Lung Disease Product
Table 118. LFB Biomedicaments Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 119. LFB Biomedicaments Recent Developments
Table 120. Abeona Therapeutics Company Details
Table 121. Abeona Therapeutics Business Overview
Table 122. Abeona Therapeutics Alpha-1 Lung Disease Product
Table 123. Abeona Therapeutics Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 124. Abeona Therapeutics Recent Developments
Table 125. Biogen Company Details
Table 126. Biogen Business Overview
Table 127. Biogen Alpha-1 Lung Disease Product
Table 128. Biogen Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 129. Biogen Recent Developments
Table 130. Vertex Pharmaceuticals Company Details
Table 131. Vertex Pharmaceuticals Business Overview
Table 132. Vertex Pharmaceuticals Alpha-1 Lung Disease Product
Table 133. Vertex Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 134. Vertex Pharmaceuticals Recent Developments
Table 135. Baxalta Company Details
Table 136. Baxalta Business Overview
Table 137. Baxalta Alpha-1 Lung Disease Product
Table 138. Baxalta Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 139. Baxalta Recent Developments
Table 140. Arrowhead Research Corporation Company Details
Table 141. Arrowhead Research Corporation Business Overview
Table 142. Arrowhead Research Corporation Alpha-1 Lung Disease Product
Table 143. Arrowhead Research Corporation Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 144. Arrowhead Research Corporation Recent Developments
Table 145. ProBioGen Company Details
Table 146. ProBioGen Business Overview
Table 147. ProBioGen Alpha-1 Lung Disease Product
Table 148. ProBioGen Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 149. ProBioGen Recent Developments
Table 150. Chiesi Pharmaceuticals Company Details
Table 151. Chiesi Pharmaceuticals Business Overview
Table 152. Chiesi Pharmaceuticals Alpha-1 Lung Disease Product
Table 153. Chiesi Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 154. Chiesi Pharmaceuticals Recent Developments
Table 155. Kedrion Group Company Details
Table 156. Kedrion Group Business Overview
Table 157. Kedrion Group Alpha-1 Lung Disease Product
Table 158. Kedrion Group Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 159. Kedrion Group Recent Developments
Table 160. ProMetic Life Sciences Company Details
Table 161. ProMetic Life Sciences Business Overview
Table 162. ProMetic Life Sciences Alpha-1 Lung Disease Product
Table 163. ProMetic Life Sciences Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 164. ProMetic Life Sciences Recent Developments
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
Table 1. Global Alpha-1 Lung Disease Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Other
Table 6. Global Alpha-1 Lung Disease Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Alpha-1 Lung Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Alpha-1 Lung Disease Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Alpha-1 Lung Disease Market Share by Region (2018-2023)
Table 10. Global Alpha-1 Lung Disease Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Alpha-1 Lung Disease Market Share by Region (2024-2029)
Table 12. Alpha-1 Lung Disease Market Trends
Table 13. Alpha-1 Lung Disease Market Drivers
Table 14. Alpha-1 Lung Disease Market Challenges
Table 15. Alpha-1 Lung Disease Market Restraints
Table 16. Global Alpha-1 Lung Disease Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Alpha-1 Lung Disease Revenue Share by Players (2018-2023)
Table 18. Global Top Alpha-1 Lung Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Lung Disease as of 2022)
Table 19. Global Alpha-1 Lung Disease Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Alpha-1 Lung Disease Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Alpha-1 Lung Disease, Headquarters and Area Served
Table 22. Global Key Players of Alpha-1 Lung Disease, Product and Application
Table 23. Global Key Players of Alpha-1 Lung Disease, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Alpha-1 Lung Disease Revenue Market Share by Type (2018-2023)
Table 27. Global Alpha-1 Lung Disease Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Alpha-1 Lung Disease Revenue Market Share by Type (2024-2029)
Table 29. Global Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Alpha-1 Lung Disease Revenue Share by Application (2018-2023)
Table 31. Global Alpha-1 Lung Disease Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Alpha-1 Lung Disease Revenue Share by Application (2024-2029)
Table 33. North America Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Alpha-1 Lung Disease Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Alpha-1 Lung Disease Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Alpha-1 Lung Disease Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Alpha-1 Lung Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size by Country (2024-2029) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Alpha-1 Lung Disease Product
Table 68. Pfizer Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 69. Pfizer Recent Developments
Table 70. Baxter Company Details
Table 71. Baxter Business Overview
Table 72. Baxter Alpha-1 Lung Disease Product
Table 73. Baxter Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 74. Baxter Recent Developments
Table 75. AstraZeneca Company Details
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Alpha-1 Lung Disease Product
Table 78. AstraZeneca Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 79. AstraZeneca Recent Developments
Table 80. Grifols Company Details
Table 81. Grifols Business Overview
Table 82. Grifols Alpha-1 Lung Disease Product
Table 83. Grifols Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 84. Grifols Recent Developments
Table 85. Teva Pharmaceutical Industries Company Details
Table 86. Teva Pharmaceutical Industries Business Overview
Table 87. Teva Pharmaceutical Industries Alpha-1 Lung Disease Product
Table 88. Teva Pharmaceutical Industries Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 89. Teva Pharmaceutical Industries Recent Developments
Table 90. Boehringer Ingelheim Company Details
Table 91. Boehringer Ingelheim Business Overview
Table 92. Boehringer Ingelheim Alpha-1 Lung Disease Product
Table 93. Boehringer Ingelheim Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 94. Boehringer Ingelheim Recent Developments
Table 95. Kamada Ltd Company Details
Table 96. Kamada Ltd Business Overview
Table 97. Kamada Ltd Alpha-1 Lung Disease Product
Table 98. Kamada Ltd Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 99. Kamada Ltd Recent Developments
Table 100. GlaxoSmithKline Company Details
Table 101. GlaxoSmithKline Business Overview
Table 102. GlaxoSmithKline Alpha-1 Lung Disease Product
Table 103. GlaxoSmithKline Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 104. GlaxoSmithKline Recent Developments
Table 105. CSL Behring Company Details
Table 106. CSL Behring Business Overview
Table 107. CSL Behring Alpha-1 Lung Disease Product
Table 108. CSL Behring Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 109. CSL Behring Recent Developments
Table 110. Takeda Company Details
Table 111. Takeda Business Overview
Table 112. Takeda Alpha-1 Lung Disease Product
Table 113. Takeda Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 114. Takeda Recent Developments
Table 115. LFB Biomedicaments Company Details
Table 116. LFB Biomedicaments Business Overview
Table 117. LFB Biomedicaments Alpha-1 Lung Disease Product
Table 118. LFB Biomedicaments Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 119. LFB Biomedicaments Recent Developments
Table 120. Abeona Therapeutics Company Details
Table 121. Abeona Therapeutics Business Overview
Table 122. Abeona Therapeutics Alpha-1 Lung Disease Product
Table 123. Abeona Therapeutics Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 124. Abeona Therapeutics Recent Developments
Table 125. Biogen Company Details
Table 126. Biogen Business Overview
Table 127. Biogen Alpha-1 Lung Disease Product
Table 128. Biogen Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 129. Biogen Recent Developments
Table 130. Vertex Pharmaceuticals Company Details
Table 131. Vertex Pharmaceuticals Business Overview
Table 132. Vertex Pharmaceuticals Alpha-1 Lung Disease Product
Table 133. Vertex Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 134. Vertex Pharmaceuticals Recent Developments
Table 135. Baxalta Company Details
Table 136. Baxalta Business Overview
Table 137. Baxalta Alpha-1 Lung Disease Product
Table 138. Baxalta Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 139. Baxalta Recent Developments
Table 140. Arrowhead Research Corporation Company Details
Table 141. Arrowhead Research Corporation Business Overview
Table 142. Arrowhead Research Corporation Alpha-1 Lung Disease Product
Table 143. Arrowhead Research Corporation Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 144. Arrowhead Research Corporation Recent Developments
Table 145. ProBioGen Company Details
Table 146. ProBioGen Business Overview
Table 147. ProBioGen Alpha-1 Lung Disease Product
Table 148. ProBioGen Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 149. ProBioGen Recent Developments
Table 150. Chiesi Pharmaceuticals Company Details
Table 151. Chiesi Pharmaceuticals Business Overview
Table 152. Chiesi Pharmaceuticals Alpha-1 Lung Disease Product
Table 153. Chiesi Pharmaceuticals Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 154. Chiesi Pharmaceuticals Recent Developments
Table 155. Kedrion Group Company Details
Table 156. Kedrion Group Business Overview
Table 157. Kedrion Group Alpha-1 Lung Disease Product
Table 158. Kedrion Group Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 159. Kedrion Group Recent Developments
Table 160. ProMetic Life Sciences Company Details
Table 161. ProMetic Life Sciences Business Overview
Table 162. ProMetic Life Sciences Alpha-1 Lung Disease Product
Table 163. ProMetic Life Sciences Revenue in Alpha-1 Lung Disease Business (2018-2023) & (US$ Million)
Table 164. ProMetic Life Sciences Recent Developments
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Alpha-1 Lung Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Alpha-1 Lung Disease Market Share by Type: 2022 VS 2029
Figure 3. Augmentation Therapy Features
Figure 4. Cystic Fibrosis(CF) Features
Figure 5. Non-CF Bronchiectasis(NCFB) Features
Figure 6. Other Features
Figure 7. Global Alpha-1 Lung Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Alpha-1 Lung Disease Market Share by Application: 2022 VS 2029
Figure 9. Hospitals Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Alpha-1 Lung Disease Report Years Considered
Figure 14. Global Alpha-1 Lung Disease Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Alpha-1 Lung Disease Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Alpha-1 Lung Disease Market Share by Region: 2022 VS 2029
Figure 17. Global Alpha-1 Lung Disease Market Share by Players in 2022
Figure 18. Global Top Alpha-1 Lung Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Lung Disease as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Alpha-1 Lung Disease Revenue in 2022
Figure 20. North America Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 22. North America Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 23. North America Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 24. United States Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 28. Europe Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 29. Europe Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 30. Germany Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 38. China Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 39. Asia Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 41. Asia Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 42. Asia Alpha-1 Lung Disease Market Share by Region (2018-2029)
Figure 43. Japan Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 53. Brazil Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 60. Baxter Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 61. AstraZeneca Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 62. Grifols Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 63. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 64. Boehringer Ingelheim Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 65. Kamada Ltd Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 67. CSL Behring Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 68. Takeda Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 69. LFB Biomedicaments Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 70. Abeona Therapeutics Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 71. Biogen Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 72. Vertex Pharmaceuticals Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 73. Baxalta Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 74. Arrowhead Research Corporation Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 75. ProBioGen Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 76. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 77. Kedrion Group Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 78. ProMetic Life Sciences Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
Figure 1. Global Alpha-1 Lung Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Alpha-1 Lung Disease Market Share by Type: 2022 VS 2029
Figure 3. Augmentation Therapy Features
Figure 4. Cystic Fibrosis(CF) Features
Figure 5. Non-CF Bronchiectasis(NCFB) Features
Figure 6. Other Features
Figure 7. Global Alpha-1 Lung Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Alpha-1 Lung Disease Market Share by Application: 2022 VS 2029
Figure 9. Hospitals Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Alpha-1 Lung Disease Report Years Considered
Figure 14. Global Alpha-1 Lung Disease Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Alpha-1 Lung Disease Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Alpha-1 Lung Disease Market Share by Region: 2022 VS 2029
Figure 17. Global Alpha-1 Lung Disease Market Share by Players in 2022
Figure 18. Global Top Alpha-1 Lung Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Lung Disease as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Alpha-1 Lung Disease Revenue in 2022
Figure 20. North America Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 22. North America Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 23. North America Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 24. United States Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 28. Europe Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 29. Europe Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 30. Germany Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 38. China Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 39. Asia Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 41. Asia Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 42. Asia Alpha-1 Lung Disease Market Share by Region (2018-2029)
Figure 43. Japan Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Alpha-1 Lung Disease Market Share by Country (2018-2029)
Figure 53. Brazil Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Alpha-1 Lung Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 60. Baxter Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 61. AstraZeneca Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 62. Grifols Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 63. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 64. Boehringer Ingelheim Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 65. Kamada Ltd Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 67. CSL Behring Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 68. Takeda Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 69. LFB Biomedicaments Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 70. Abeona Therapeutics Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 71. Biogen Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 72. Vertex Pharmaceuticals Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 73. Baxalta Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 74. Arrowhead Research Corporation Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 75. ProBioGen Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 76. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 77. Kedrion Group Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 78. ProMetic Life Sciences Revenue Growth Rate in Alpha-1 Lung Disease Business (2018-2023)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
